3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
4
Phase 1
3
Phase 4
1
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
3
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Breast Neoplasms
1
Interventions
niraparib
4
olaparib
2
apatinib
2
Sevoflurane
2
Saline Solution
2
Propofol
2
Carboplatin
2
Bevacizumab
2
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
palbociclib
1
liposomal doxorubicin
1
lenvatinib
1
gadofosveset trisodium
1
fosaprepitant
1
ferrous fumarate
1
Tranexamic Acid
1
Trabectedin
1
Sunitinib
1
Sodium Chloride
1
Pharmacokinetics
1
Patient-Specific Modeling
1
Pafolacianine
1
Paclitaxel
1
LY 353381
1
Injections
1
Indocyanine Green
1
Folic Acid
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Ovarian Neoplasms
×
pazopanib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled